Posted by Michael Wonder on 28 Aug 2017
NICE terminates appraisal of another cancer medicine
23 August 2017 - NICE has terminated its appraisal of idelalisib with ofatumumab acetate for the treatment of patients with chronic lymphocytic leukaemia.
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received from Gilead Sciences.
NICE will review this decision if Gilead decides to make a submission.
